Fig. 4: Lysosomal sequestration of sunitinib. | British Journal of Cancer

Fig. 4: Lysosomal sequestration of sunitinib.

From: CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma

Fig. 4

a 786-O cells were treated with sunitinib with or without lonafarnib, stained with Hoechst and Lysotracker Red, and imaged as described in “Methods”. b 786-O cells were treated as described in a. The number of sunitinib containing vesicles per cell was calculated as described in Materials and Methods. Data are presented as the mean ± S.D. ***P < 0.0001. c The total cellular accumulation of sunitinib was not affected by lonafarnib. 786-O cells were treated as described in a. The samples were run on Becton Dickinson FACScan flow cytometer and analysed using FlowJo software.

Back to article page